Target intelligence / Profile preview

Chymotrypsin-like elastase family member 2A (CELA2A)

Target
CELA2A
Molecular classification
Enzyme, Serine protease, Hydrolase
01

Overview

Chymotrypsin-like elastase family member 2A (CELA2A) is a pancreatic serine protease enzyme secreted as a zymogen that hydrolyzes proteins, especially elastin, as well as proteins containing leucine, methionine, and phenylalanine residues. Beyond its canonical digestive role, CELA2A circulates in plasma where it modulates postprandial metabolic signaling. It reduces platelet hyperactivation, triggers both insulin secretion and insulin degradation, increases insulin sensitivity, and is implicated in the pathogenesis of metabolic syndrome and early-onset atherosclerosis when mutated. These diverse effects position CELA2A as an attractive target for therapeutic intervention in metabolic and cardiovascular diseases

Other names
ELA2AElastase-2APancreatic elastase 2Pancreatic elastase IIAPE-1chymotrypsin-like elastase family member 2Aelastase 2AAOMS4CELA2A
02

Mechanism of action

Drugs targeting CELA2A would be expected to modulate its protease activity, and thereby influence insulin secretion, insulin degradation, platelet activation, and metabolic homeostasis

03

Biological functions

Digestive proteolysis (hydrolyzes proteins including elastin)Regulation of digestive enzyme activation (zymogen activation)Enhancement of insulin signalingIncreases insulin sensitivityTriggers both insulin secretion and degradationReduces platelet hyperactivation
04

Disease associations

Metabolic syndromeEarly-onset atherosclerosisAbdominal obesity-metabolic syndrome 4Coronary artery diseasePotential link to diabetes and its complications
05

Safety considerations

Therapeutic modulation must account for potential impact on digestive function, glucose metabolism, and platelet activity
06

Interacting drugs

No direct drugs currently listed; CELA2A is considered a potential emerging therapeutic target for metabolic syndrome and diabetes
07

Biomarkers

CELA2A mutations and plasma levels may serve as biomarkers for metabolic syndrome, early-onset atherosclerosis, and insulin sensitivity

Beyond the preview

Go deeper on Chymotrypsin-like elastase family member 2A (CELA2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chymotrypsin-like elastase family member 2A (CELA2A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call